Xencor Inc. ((XNCR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Xencor Inc. is conducting a Phase 1 study titled ‘A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma.’ The study aims to assess the safety and tolerability of XmAb819, a monoclonal bispecific antibody, in patients with advanced renal cell carcinoma, and to determine the minimum safe and biologically active dose.
Intervention/Treatment: The intervention being tested is XmAb819, a biological treatment designed as a monoclonal bispecific antibody. Its purpose is to treat patients with relapsed or refractory clear cell renal cell carcinoma by establishing a safe and effective dosing schedule.
Study Design: This is an interventional study with a sequential intervention model and no masking. The primary purpose is treatment. The study consists of two parts: dose escalation to determine the dosing schedule, and dose expansion to further assess the treatment’s efficacy.
Study Timeline: The study began on June 13, 2022, and is currently recruiting participants. The last update was submitted on July 28, 2025. These dates are crucial as they mark the study’s progress and the timeline for potential results.
Market Implications: The ongoing study of XmAb819 could significantly impact Xencor Inc.’s stock performance, as positive results may boost investor confidence and interest. In the competitive landscape of cancer treatments, advancements in this study could position Xencor favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.